List view / Grid view
Researchers have discovered that patients with alcoholic hepatitis had high numbers of a destructive gut bacterium and they were able to use a cocktail of phages to target and kill the bacteria, eradicating the disease.
Researchers have created an AI model that analyses the citations of studies, predicting their potential for eventual clinical application.
Scientists in the US have developed a promising new CAR T-cell therapy that targets the BAFF-R protein, which has demonstrated superior cancer destruction to existing FDA-approved CAR-T therapies.
The memory of mice with Alzheimer's greatly improved after they were injected with two newly discovered short peptides.
A new drug discovery strategy predicts the clinical actions of new compounds to promote desired clinical responses and avoid side effects.
A potential treatment for polycystic kidney disease has shown positive results in animal testing.
Researchers have developed a new cocktail of drugs that shrink pancreatic tumours in mice by blocking pathways that cancer cells use.
This issue includes an investigation into utilising recombinant antibodies for research, a highlight on protein design using computational methods and an examination of the advances in genomic medicine. Also in the issue are articles on next generation sequencing and upstream bioprocessing.
The British Journal of Pharmacology has recommended that all studies it publishes should address sex as an experimental variable.
Researchers have developed a new AI system which was able to discover and then successfully test several new compounds within 46 days.
Australian researchers have demonstrated the success of a novel TB vaccine in mice, which could provide another treatment option for the disease.
Researchers have found that inhibiting a kinase in mice leads to the death of prostate cancer cells, providing a potential therapeutic target.
Two genes that influence risk Alzheimer's disease could provide scientists with new targets for delaying the onset of the condition's symptoms.
The first genetically modified mini human livers have been grown in a laboratory, to emulate liver disease progression and test therapeutics.
Researchers hope the system can choose the right patients to enroll in clinical trials, to speed discovery of drug treatments.
